Cargando…

In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody

With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c‐erbB‐2 gene product, and the other arm recognized CD3ɛ, a T‐cell specific surface antigen. Application of this BFA wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugiyama, Yoshihiro, Aihara, Miki, Shibamori, Masafumi, Deguchi, Kyohei, Imagawa, Kenichi, Kikuchi, Mikio, Momota, Hiroshi, Azuma, Takachika, Okada, Hidechika, Alper, Özge, Hitomi, Jiro, Yamaguchi, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1992
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918874/ https://www.ncbi.nlm.nih.gov/pubmed/1353752 http://dx.doi.org/10.1111/j.1349-7006.1992.tb00126.x

Ejemplares similares

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017)

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
por: Adams, Stephen R., et al.
Publicado: (2016)

Detection of the Ligand Activity of the c‐erbB‐2 Protein in Calf Serum
por: Shan, RuJiao, et al.
Publicado: (1992)

The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012)

A Murine Monoclonal Antibody that Recognizes an Extracellular Domain of the Human c‐erbB‐2 Protooncogene Product
por: Masuko, Takashi, et al.
Publicado: (1989)

An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
por: Lu, Qiong, et al.
Publicado: (2016)

Co‐amplification of c‐myc and c‐erbB‐2 Oncogenes in a Poorly Differentiated Human Gastric Cancer
por: Tsuchiya, Terumasa, et al.
Publicado: (1989)

ErbB2 Dephosphorylation and Anti-Proliferative Effects of Neuregulin-1 in ErbB2-Overexpressing Cells; Re-evaluation of Their Low-Affinity Interaction
por: Wang, Ran, et al.
Publicado: (2013)

Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
por: Lin, Tingting, et al.
Publicado: (2019)

Improvement of Gelatin Particle Agglutination Test for Detection of Anti‐HTLV‐I Antibody
por: Fujino, Ryuichi, et al.
Publicado: (1991)

Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways
por: Pugatsch, Thea, et al.
Publicado: (2006)

Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody
por: Wang, Chao, et al.
Publicado: (2017)

Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy
por: De Santis, Rita
Publicado: (2020)

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
por: Ciardiello, Chiara, et al.
Publicado: (2016)

Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities
por: Gu, Jinming, et al.
Publicado: (2015)

Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells.
por: Suzuki, S., et al.
Publicado: (1995)

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
por: Gelardi, T, et al.
Publicado: (2010)

Neuregulin 1/ErbB4 signaling contributes to the anti-epileptic effects of the ketogenic diet
por: Wang, Jin, et al.
Publicado: (2021)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2(+) Solid Cancer
por: Hombach, Andreas A., et al.
Publicado: (2023)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Human Tumor Growth Suppression by Apoptosis Induced with Anti‐ErbB‐2 Chimeric Monoclonal Antibody
por: Sasaki, Shigeru, et al.
Publicado: (1998)

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
por: De Lorenzo, Claudia, et al.
Publicado: (2018)

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
por: Fattore, Luigi, et al.
Publicado: (2013)

Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody.
por: Ohnishi, Y., et al.
Publicado: (1995)

A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent
por: De Lorenzo, C, et al.
Publicado: (2004)

Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig™) Proteins with Unique Activities
por: Gu, Jinming, et al.
Publicado: (2014)

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer
por: Wang, Lingfei, et al.
Publicado: (2017)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.
por: Tokuda, Y., et al.
Publicado: (1996)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

The Role of ErbB Receptors in Infection
por: Ho, Jemima, et al.
Publicado: (2017)

FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
por: Benlimame, Naciba, et al.
Publicado: (2005)

ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
por: Moghbeli, Meysam, et al.
Publicado: (2019)

Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma
por: Redlich, Nathan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_42r3ch20hpnka9mvk6ou8f9ahu